Clinical trial
Lymphocyte to Procalcitonin Ratio: A New Predictor of Prognosis and Mortality in Covid
NCT06620159 is registered in ClinicalTrials.gov with Suleyman Demirel University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Lymphocyte to Procalcitonin Ratio: A New Predictor of Prognosis and Mortality in Covid
- Lead sponsor
- Suleyman Demirel University
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- April 1, 2020
- Completion date
- December 1, 2024
- Enrollment
- 535 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.